Follow Us
https://www.thebody.com/article/promise-and-peril-the-new-hep-c-drugs
    Promise and Peril: The New Hep C Drugs
    Sovaldi
    The SYNERGY trial showed that close to 100% of people starting HCV treatment for the first time can be cured with two DAAs taken once daily for 12 weeks or three DAAs taken for just six weeks.
    Share
    Janssen and Gilead have both taken heat for their high prices. Sovaldi's $1,000-per-pill price tag has drawn attention well beyond the usual ranks of activists, with criticism coming from medical providers, insurance companies, and legislators.
    Share
    Sovaldi protest
    Liz Highleyman

    Liz Highleyman

    AIDS Community Research Initiative of America

    AIDS Community Research Initiative of America

    ACRIA's mission is to pioneer the newest HIV prevention and health education, and get that information into the hands of the people who need it the most.